Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Complaint Alleges Spectrum Pharmaceuticals Failed to Disclose Negative Data from Clinical Trials

ONTARIO, Calif., Dec. 9, 2022 /PRNewswire/ -- McCune law Group, McCune Wright Arevalo Vercoski Kusel Weck Brandt APC (MLG) – a national law firm specializing in Securities Litigation , Commercial Litigation , and Class Actions, - is investigating bringing claims on behalf of purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") common stock between December 6, 2021, and September 22, 2022, both dates inclusive (the "Class Period"). The complaint alleges that during the Class Period, Spectrum made false and/or misleading statements and/or failed to disclose negative data on the safety and efficacy of pozi, and the Company's failure to enroll patients in an FDA-required phase 3 confirmatory trial. The complaint has been filed in the United States District Court for the Southern District of New York, and is captioned Osorio-Franco v. Spectrum Pharmaceuticals, Inc. et al., No. 1:22-cv-10292 (S.D.N.Y. Dec 05, 2022).

The complaint also alleges that Spectrum was conducting a phase 2 clinical trial called ZENITH20 evaluating poziotinib, or "pozi", in patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with certain mutations and who were previously treated with the standard of care and had submitted a New Drug Application ("NDA") to...

Read Full Story: https://news.google.com/__i/rss/rd/articles/CBMivgFodHRwczovL3d3dy5zdHJlZXRpb...